ID
45396
Description
Principal Investigator: Dan Roden, MD, Vanderbilt University Medical Center, Nashville, TN, USA MeSH: Long QT Syndrome,Torsades de Pointes https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000617 The goal of this study was to search for genetic variants that could be responsible for modifying the risk of drug-induced long QT syndrome (diLQTS). diLQTS is a relatively common adverse drug event and has been a leading cause for drug relabeling and withdrawal from the market. Our hypothesis, that variants in genes which regulate electrical properties in the heart modify the risk of diLQTS, was tested by genotyping patients of European descent at 1424 single nucleotide polymorphisms (SNPs) in 18 candidate genes. We found that the SNP KCNE1 D85N was highly predictive of diLQTS with an odds ratio of 9.0 (95% confidence interval: 3.5-22.9).
Lien
Mots-clés
Versions (1)
- 15/11/2022 15/11/2022 - Simon Heim
Détendeur de droits
Dan Roden, MD, Vanderbilt University Medical Center, Nashville, TN, USA
Téléchargé le
15 novembre 2022
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
dbGaP phs000617 KCNE1Polymorphism as Possible Modulator of Drug-Induced TdP
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with or without QT syndrome and involved in the "PGRN-Leducq: Identification of the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes" project.
- Subject ID, sample ID, and sample use variable obtained from participants with or without QT syndrome and involved in the "PGRN-Leducq: Identification of the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes" project.
- Subject ID, case or control, gender, ethnicity, age of participant at time of drug challenge, history of hypertension, heart failure, atrial fibrillation, ejection fraction, serum creatinine level, and serum potassium of participants with or without QT syndrome and involved in the "PGRN-Leducq: Identification of the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes" project.
- Sample ID, body site where sample was collected, analyte type, and tumor status of sample obtained from participants with or without QT syndrome and involved in the "PGRN-Leducq: Identification of the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with or without QT syndrome and involved in the "PGRN-Leducq: Identification of the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes" project.
- Subject ID, sample ID, and sample use variable obtained from participants with or without QT syndrome and involved in the "PGRN-Leducq: Identification of the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes" project.
- Subject ID, case or control, gender, ethnicity, age of participant at time of drug challenge, history of hypertension, heart failure, atrial fibrillation, ejection fraction, serum creatinine level, and serum potassium of participants with or without QT syndrome and involved in the "PGRN-Leducq: Identification of the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes" project.
- Sample ID, body site where sample was collected, analyte type, and tumor status of sample obtained from participants with or without QT syndrome and involved in the "PGRN-Leducq: Identification of the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes" project.
C0680251 (UMLS CUI [1,2])
C1706256 (UMLS CUI [1,2])
C0001779 (UMLS CUI [1,3])
C0023976 (UMLS CUI [1,4])
C0458082 (UMLS CUI [1,5])
C0040479 (UMLS CUI [1,6])
C0151878 (UMLS CUI [1,2])
C1287082 (UMLS CUI [2,1])
C1395815 (UMLS CUI [2,2])
C0443172 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
C0347984 (UMLS CUI [1,4])
C0457083 (UMLS CUI [1,5])
C1287082 (UMLS CUI [2,1])
C0443172 (UMLS CUI [2,2])
C0347984 (UMLS CUI [2,3])
C0687676 (UMLS CUI [2,4])
C0457083 (UMLS CUI [2,5])
C0040479 (UMLS CUI [1,2])
C2349954 (UMLS CUI [2,1])
C0332125 (UMLS CUI [2,2])
C0040479 (UMLS CUI [2,3])
C1706256 (UMLS CUI [1,2])
C0332162 (UMLS CUI [1,2])
C0441471 (UMLS CUI [1,3])
C0332162 (UMLS CUI [1,2])
C0441471 (UMLS CUI [1,3])
C4035156 (UMLS CUI [1,2])
C0332162 (UMLS CUI [1,3])
C0441471 (UMLS CUI [1,4])
C0020672 (UMLS CUI [1,2])
C0332162 (UMLS CUI [1,3])
C0441471 (UMLS CUI [1,4])
C0332152 (UMLS CUI [1,2])
C0332162 (UMLS CUI [1,3])
C0441471 (UMLS CUI [1,4])
C0023530 (UMLS CUI [1,2])
C1444637 (UMLS CUI [1,2])
C0009932 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])
C0003195 (UMLS CUI [1,3])
C0151878 (UMLS CUI [1,4])
C3845783 (UMLS CUI [1,2])